Amgen Inc. (AMGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
173.53-1.27 (-0.73%)
At close: 4:00 PM EDT

173.53 0.00 (0.00%)
After hours: 4:43 PM EDT

People also watch:
BIIBGILDCELGMRKBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open174.22
Prev Close174.80
Bid172.50 x 4000
Ask173.75 x 5000
Day's Range172.83 - 174.42
52wk Range130.09 - 176.85
1y Target EstN/A
Market Cap129.86B
P/E Ratio (ttm)17.76
Beta1.34
Volume1,548,409
Avg Vol (3m)2,864,382
Dividend & Yield4.00 (2.29%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • TheStreet.com46 minutes ago

    Wall Street Sells Off on Worries Over Clinton-Trump Showdown

    Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.

  • PR Newswire49 minutes ago

    Amgen And UCB Announce U.S. FDA Acceptance Of Biologics License Application For Romosozumab

    THOUSAND OAKS, Calif. and BRUSSELS, Sept. 26, 2016 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for romosozumab, an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. "We believe romosozumab could serve as an important therapeutic option for osteoporosis patients with an increased risk of fracture," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. The BLA, submitted on July 19, 2016, is based on data from the pivotal Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME) in approximately 7,200 patients.

  • TheStreet.com2 hours ago

    Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

    Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.